Lurasidone for bipolar I depression with comorbid anxiety symptoms: Post-hoc-analysis of randomized, placebo-controlled studies
This analysis suggests that lurasidone 20-60 mg is effective in patients with bipolar I depression regardless of their anxiety severity, with a generally good safety profile.
Authors
- Hidenori Maruyama (ORCID: https://orcid.org/0000-0002-1356-8100)
- Takahiro Masuda (ORCID: https://orcid.org/0000-0002-2225-6619)
- Takeshi Inoue (ORCID: https://orcid.org/0000-0001-5248-1289)
- Fumiya Sano (ORCID: https://orcid.org/0000-0002-2634-1597)
Institutions
- Sumitomo Dainippon Pharma (Japan) (JP)
- Sapporo Medical University Hospital (JP)
- Hanazono Hospital (JP)
Publication Details
- Journal
- Journal of Affective Disorders
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1016/j.jad.2025.05.008
- Citations
- 1
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47